Entero Therapeutics, Inc.

NasdaqCM:ENTO 株式レポート

時価総額:US$2.2m

Entero Therapeutics 将来の成長

Future 基準チェック /06

Entero Therapeutics is forecast to grow earnings and revenue by 5.9% and 95.3% per annum respectively while EPS is expected to grow by 46.2% per annum.

主要情報

5.9%

収益成長率

46.2%

EPS成長率

Biotechs 収益成長27.1%
収益成長率95.3%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日27 Sep 2024

今後の成長に関する最新情報

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

Jun 07

AzurRx BioPharma: An Assessment

May 02

AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio

Jan 31

業績と収益の成長予測

NasdaqCM:ENTO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2026N/A-42N/AN/A1
12/31/2025N/A-32N/AN/A1
12/31/2024N/A-11N/AN/A1
6/30/2024N/A-10-14-14N/A
3/31/2024N/A-6-14-13N/A
12/31/2023N/A-16-13-12N/A
9/30/2023N/A-16-15-15N/A
6/30/2023N/A-8-15-15N/A
3/31/2023N/A-9-17-17N/A
12/31/2022N/A-15-22-22N/A
9/30/2022N/A-22-33-23N/A
6/30/2022N/A-57-44-34N/A
3/31/2022N/A-65-45-35N/A
12/31/2021N/A-85-43-32N/A
9/30/2021N/A-92-32-32N/A
6/30/2021N/A-74-19-19N/A
3/31/2021N/A-66-15-15N/A
12/31/2020N/A-42-11-11N/A
9/30/2020N/A-25-9-9N/A
6/30/2020N/A-15-10-10N/A
3/31/2020N/A-16-13-13N/A
12/31/2019N/A-15-14-14N/A
9/30/2019N/A-18-14-14N/A
6/30/2019N/A-16-13-13N/A
3/31/2019N/A-15-12-11N/A
12/31/2018N/A-14-11-11N/A
9/30/2018N/A-12-10-10N/A
6/30/2018N/A-13-9-9N/A
3/31/2018N/A-12N/A-8N/A
12/31/2017N/A-11N/A-7N/A
9/30/2017N/A-14N/A-7N/A
6/30/2017N/A-14N/A-7N/A
3/31/2017N/A-15N/A-5N/A
12/31/2016N/A-15N/A-5N/A
9/30/2016N/A-10N/A-3N/A
6/30/2016N/A-8N/A-4N/A
3/31/2016N/A-7N/A-4N/A
12/31/2015N/A-6N/A-4N/A
9/30/2015N/A-6N/A-4N/A
6/30/2015N/A-5N/A-3N/A
3/31/2015N/A-3N/A-2N/A
12/31/2014N/A-2N/A-1N/A

アナリストによる今後の成長予測

収入対貯蓄率: ENTO is forecast to remain unprofitable over the next 3 years.

収益対市場: ENTO is forecast to remain unprofitable over the next 3 years.

高成長収益: ENTO is forecast to remain unprofitable over the next 3 years.

収益対市場: ENTO is forecast to have no revenue next year.

高い収益成長: ENTO is forecast to have no revenue next year.


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: Insufficient data to determine if ENTO's Return on Equity is forecast to be high in 3 years time


成長企業の発掘